These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 29098953

  • 1. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
    Kaya AH, Tekgündüz E, Ilkkiliç K, Dal MS, Merdin A, Karakus A, Hacioglu SK, Bekdemir F, Çakar MK, Dogu MH, Ayyildiz MO, Korkmaz S, Altuntaş F, On the behalf of The Turkish Hematology Research and Edication Group (ThREG).
    J Chemother; 2018 Feb; 30(1):44-48. PubMed ID: 29098953
    [Abstract] [Full Text] [Related]

  • 2. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hänel A, Morgner A, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hänel M, East German Study Group Hematology/Oncology (OSHO), Study Alliance Leukemia (SAL).
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [Abstract] [Full Text] [Related]

  • 3. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H.
    Cancer; 2017 Nov 15; 123(22):4430-4439. PubMed ID: 28708931
    [Abstract] [Full Text] [Related]

  • 4. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
    Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernandez J, García R, García-Huerta AJ, Barrios M, Benavente C, Pérez-Encinas M, Simiele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Riaza-Grau R, Sanz MA, PETHEMA group.
    Br J Haematol; 2016 Sep 15; 174(5):700-10. PubMed ID: 27118319
    [Abstract] [Full Text] [Related]

  • 5. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
    Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA.
    Clin Lymphoma Myeloma Leuk; 2021 Jul 15; 21(7):e611-e618. PubMed ID: 33811007
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep 15; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 7. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.
    Am J Hematol; 2015 Apr 15; 90(4):295-300. PubMed ID: 25545153
    [Abstract] [Full Text] [Related]

  • 8. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.
    Am J Hematol; 2009 Nov 15; 84(11):733-7. PubMed ID: 19806665
    [Abstract] [Full Text] [Related]

  • 9. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL, Talpaz M, Perissinotti AJ.
    Ann Hematol; 2018 Apr 15; 97(4):573-584. PubMed ID: 29288428
    [Abstract] [Full Text] [Related]

  • 10. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
    Quarello P, Berger M, Rivetti E, Galletto C, Masetti R, Manicone R, Barisone E, Pession A, Fagioli F.
    J Pediatr Hematol Oncol; 2012 Apr 15; 34(3):208-16. PubMed ID: 22395219
    [Abstract] [Full Text] [Related]

  • 11. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.
    Onkologie; 2001 Aug 15; 24(4):356-60. PubMed ID: 11574763
    [Abstract] [Full Text] [Related]

  • 12. Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.
    Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH.
    Haematologica; 2013 Jan 15; 98(1):114-8. PubMed ID: 22801963
    [Abstract] [Full Text] [Related]

  • 13. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
    Bao Y, Zhao J, Li ZZ.
    Clin Transl Oncol; 2018 Jul 15; 20(7):870-880. PubMed ID: 29181696
    [Abstract] [Full Text] [Related]

  • 14. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
    Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.
    J Clin Oncol; 2017 Apr 10; 35(11):1223-1230. PubMed ID: 28221862
    [Abstract] [Full Text] [Related]

  • 15. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H, Youk J, Kim I, Yoon SS, Park S, Lee JO, Bang SM, Koh Y.
    Ann Hematol; 2016 Oct 10; 95(11):1777-86. PubMed ID: 27539617
    [Abstract] [Full Text] [Related]

  • 16. Clofarabine combinations as acute myeloid leukemia salvage therapy.
    Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM.
    Cancer; 2008 Oct 15; 113(8):2090-6. PubMed ID: 18756533
    [Abstract] [Full Text] [Related]

  • 17. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.
    Ann Hematol; 2014 Dec 15; 93(12):2011-8. PubMed ID: 24989345
    [Abstract] [Full Text] [Related]

  • 18. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A.
    Am J Hematol; 2012 Dec 15; 87(12):1047-51. PubMed ID: 23151979
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A, Wei A.
    Leuk Lymphoma; 2013 Feb 15; 54(2):336-41. PubMed ID: 22812445
    [Abstract] [Full Text] [Related]

  • 20. FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.
    Eom KS, Min WS, Kim HJ, Cho BS, Choi SM, Lee DG, Lee S, Min CK, Kim YJ, Cho SG, Lee JW, Kim CC.
    Med Oncol; 2011 Dec 15; 28 Suppl 1():S462-70. PubMed ID: 20714942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.